Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q3 2024 · 10-Q
Revenue$115.00K$115.00K−73.2% vs Q3 2023 Net Income-$13.49M-$13.49MN/M vs Q3 2023 EPS Diluted-$0.98-$0.98N/M vs Q3 2023 Gross Profit$50,000−79.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,530,000N/M Free Cash Flowderived-$5,617,000— Margins · derivedGross margin43.5%−14.3 pt vs Q3 2023
Operating margin-11752.2%−10234.0 pt vs Q3 2023
Net margin-11733.0%−10220.5 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end